Using this in vitro chip model, we can study CFRD and glucose imbalance in CF individuals, assay variability in the glucose measures in these individuals, determine correlation of glucose levels with the CFTR mutation type, and test small-molecule interventions (i.e., approved CFTR modulators) that may improve glucose abnormalities in the patient samples. Here, CFTR is linked to cystic fibrosis-related diabetes.